U.S. markets closed

Check-Cap Ltd. (CHEK)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
1.2500+0.1000 (+8.70%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
Previous Close1.1500
Open1.1700
Bid1.2400 x 2900
Ask1.2300 x 1400
Day's Range1.0000 - 1.3000
52 Week Range0.2430 - 2.9300
Volume6,485,386
Avg. Volume19,664,491
Market Cap57.797M
Beta (5Y Monthly)0.13
PE Ratio (TTM)N/A
EPS (TTM)-0.6600
Earnings DateNov 18, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Check-Cap Issues Letter to Shareholders
    PR Newswire

    Check-Cap Issues Letter to Shareholders

    Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer, today issued the following letter from its chief executive officer, Alex Ovadia to its shareholders and the investment community:

  • Is Check-Cap (NASDAQ:CHEK) In A Good Position To Invest In Growth?
    Simply Wall St.

    Is Check-Cap (NASDAQ:CHEK) In A Good Position To Invest In Growth?

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • Check-Cap Reports Third Quarter 2020 Financial Results and Corporate Highlights
    PR Newswire

    Check-Cap Reports Third Quarter 2020 Financial Results and Corporate Highlights

    Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer, today announced financial results for the third quarter and nine months ended September 30, 2020 and corporate highlights.